Lineagotica Associate Editors share new insights from research presented at the 2019 ASCO Annual Meeting.
ASCO Annual Meeting 2019: Immunotherapy for Lung Cancer, Gastrointestinal Cancers and Targeted Therapy for Breast Cancer
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.
Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.
Kimberly Pena was 31 when she was diagnosed with breast cancer, the same age her mother was when she was diagnosed more than 3 decades earlier. She shares her experience with cancer, treatment, and trying to convince her family to be tested for the BRCA genetic mutation.
Three years ago, Sara Tejeda was pregnant, with another child in intensive care, when she was diagnosed with breast cancer. In this interview, she shares the story of how she came through the pain and loss.
Dr. Bárbara Segarra-Vázquez’s breast cancer diagnosis in 2003 has led to a career of advocacy in cancer research as well as bringing the Hispanic experience to cancer clinicians.
In this podcast interview, Dr. Allison W. Kurian talks about a recent study showing that most women with breast or ovarian cancer do not receive genetic testing.
Cancer can affect anyone, including young adults and teens. In these “Your Stories” podcasts from ASCO’s Conquer Cancer Foundation, two survivors tell their stories about when a diagnosis of cancer changed everything.
Can immunotherapy be used to treat breast cancer? This expert Q&A explains.
In this podcast, Lineagotica Associate Editor Dr. Lynn Henry describes a clinical trial that studied a new approach to treating HER2-positive breast cancer.